Amgen, Inc. vs MGM Resorts International — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while MGM Resorts International trades at $44.5 (market cap $11.10B). The key difference: Amgen, Inc. is far larger — about 20.2× MGM Resorts International's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | MGM | |
|---|---|---|
Market Cap | $224.14B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $50.69 |
52-Week Low | $271.18 | $30.72 |
Enterprise Value | $267.45B | $38.40B |
Dividend Yield | 2.43% | 0.03% |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
MGM Resorts International (MGM) trades at $43.915, up 1.28% on the day, with a bearish technical signal and neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.59 per share versus $0.63 expected, though revenue hit a record. The company faces a shareholder investigation into Barry Diller's proposed acquisition at $48.30 per share. Fundamentals show a P/E of 26.75 and net income margin of 2.4%, with revenue growth to $17.54B in 2025.
The outlook is mixed: analyst consensus targets $51.14 with 49% buy ratings, but technicals and acquisition uncertainty pose risks. Upside hinges on Las Vegas recovery and BetMGM's iGaming expansion, while margin pressures and legal probes are headwinds. Cash flow trends improved to a projected net positive $572M in 2026, supporting stability.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →